M005
S-(+)-Deprenyl hydrochloride
solid
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C13H17N · HCl
CAS Number:
Molecular Weight:
223.74
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
form
solid
optical activity
[α]24/D +11.84°, c = 0.1 in H2O(lit.)
color
white
solubility
H2O: soluble
SMILES string
Cl.C[C@@H](Cc1ccccc1)N(C)CC#C
Biochem/physiol Actions
Less active enantiomer of deprenyl.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J W Tetrud et al.
Science (New York, N.Y.), 245(4917), 519-522 (1989-08-04)
The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's disease, can be fully prevented in experimental animals by inhibiting monoamine oxidase B. On the basis of this observation, a double-blind, placebo-controlled study in patients with early
R E Heikkila et al.
Nature, 311(5985), 467-469 (1984-10-04)
1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) causes degeneration of the dopaminergic nigrostriatal pathway in several animal species, including humans, monkeys and mice. Changes observed after MPTP administration include marked decrements in the neostriatal content of dopamine and its major metabolites, dihydroxyphenylacetic acid and homovanillic
Jorge A Zavala et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 19(9), 1298-1299 (2012-06-23)
Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease. Common side effects are daytime drowsiness, hypotension, hallucinations and compulsive behaviour. We describe a patient who developed
Wakako Maruyama et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(1), 83-89 (2012-08-16)
Neuroprotection has been proposed in neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases, to delay or halt disease progression or reverse neuronal deterioration. The inhibitors of type B monoamine oxidase (MAO), rasagiline and (-)deprenyl, prevent neuronal loss in cellular and
Retention rate of selegiline in early Parkinson's disease: a retrospective survey.
T Keränen et al.
International journal of clinical practice, 66(10), 1014-1014 (2012-09-22)
Chromatograms
application for HPLC
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service